@bananapranks.99: Free wali biryani#bananapranks #bananaprank #foryou #viral #treanding #foryoupageofficiall #smile #haha #shortstory #funny #funny #comedy #comadyindia #shortstory

Banana Pranks
Banana Pranks
Open In TikTok:
Region: PK
Thursday 21 December 2023 03:10:12 GMT
70477
2059
15
15

Music

Download

Comments

awaisjutt721gb
Awais jutt :
very nice
2023-12-21 04:29:41
3
dmbhai84
Dmbhai24 :
😂😂😂😂
2023-12-21 09:41:40
4
awaisjutt721gb
Awais jutt :
💓💓💓💓
2023-12-21 04:29:27
3
malikwaqar34530
malik waqar :
🤣🤣😂🤣🤣🤣
2023-12-22 18:51:59
2
muhammad.omer.langah
Muhammad omer Langah :
🥰🥰🥰🥰🥰
2023-12-21 16:45:23
1
yunis.khan7550
Yunis Khan7550 :
🥰🥰🥰
2024-11-29 07:51:14
0
zubairstoreoffcial
user07820020077 :
🥰
2025-05-06 03:38:29
0
yunis.khan7550
Yunis Khan7550 :
🥰🥰🥰
2024-11-29 07:51:08
0
yunis.khan7550
Yunis Khan7550 :
😂😂😂
2024-11-29 07:51:13
0
yunis.khan7550
Yunis Khan7550 :
😁😁😁
2024-11-29 07:51:13
0
userhamzakhan040
حمزہ خان :
🥰🥰🥰
2024-08-07 06:40:09
0
user560248861
Farhan Ali❤️💓user560248861 :
😳😳😳
2024-01-04 19:29:57
0
waqeeralimagsiwaq
meer waqar magsi :
😂😂😂😂😅😅😅😅😅😅😅😅
2023-12-25 17:10:07
0
naseerali406
Naseer Ali :
♥️
2025-04-01 10:25:53
0
dhanibux2275
Dhani bux :
🥰
2026-02-06 20:39:13
0
To see more videos from user @bananapranks.99, please go to the Tikwm homepage.

Other Videos

Are GLP-1 receptor agonists (like semaglutide and tirzepatide) doing more than just driving weight loss and glycemic control? Emerging observational studies and clinical trials suggest they may reduce the incidence of obesity-associated cancers and improve overall survival in active cancer patients! Let's break down the scientific mechanisms: 🩺🫁👇
 
 Hi, I'm Dr. Cleo Riles, Harvard-trained cancer researcher and science communicator. Welcome to Part 1 of my ongoing GLP-1s & Cancer Research Series:
 
 🧬 1. THE METABOLIC & TUMOR INTERSECTION:
 
 13 Obesity-Associated Cancers: Obesity drives chronic low-grade inflammation, hyperinsulinemia, elevated IGF-1 (insulin-like growth factor 1), and altered adipokines (leptin/adiponectin ratio)—all of which promote tumor cell proliferation and angiogenesis.
 
 Direct vs. Indirect Pathways: GLP-1s lower cancer risk indirectly through substantial adiposity loss and improved insulin sensitivity. However, researchers are also investigating direct GLP-1 receptor signalling in immune cells (e.g., NK cell restoration) and tumor microenvironments.
 
 📊 2. WHAT THE EARLY SIGNALS SHOW:
 
 Incidence Reduction: Large retrospective cohort studies show significant risk reductions in colorectal, pancreatic, endometrial, ovarian, and breast cancers compared to traditional anti-diabetic medications like insulin or sulfonylureas.
 
 Active Cancer Outcomes: Emerging studies are evaluating whether GLP-1 use during or after active treatment improves recurrence-free survival (RFS) and treatment response (e.g., reversing chemotherapy resistance driven by metabolic dysfunction).
 
 🔬 3. WHAT TO WATCH FOR IN THIS SERIES:
 Over the next several weeks, I'll be breaking down landmark studies, real-world comparative effectiveness data, and my own upcoming research presentation on GLP-1 use and breast cancer outcomes!
 
 👇 What questions do you have about GLP-1 medications and cancer risks? Leave them below!
 #GLP1 #Oncology #CancerResearch #Ozempic #Wegovy
Are GLP-1 receptor agonists (like semaglutide and tirzepatide) doing more than just driving weight loss and glycemic control? Emerging observational studies and clinical trials suggest they may reduce the incidence of obesity-associated cancers and improve overall survival in active cancer patients! Let's break down the scientific mechanisms: 🩺🫁👇 Hi, I'm Dr. Cleo Riles, Harvard-trained cancer researcher and science communicator. Welcome to Part 1 of my ongoing GLP-1s & Cancer Research Series: 🧬 1. THE METABOLIC & TUMOR INTERSECTION: 13 Obesity-Associated Cancers: Obesity drives chronic low-grade inflammation, hyperinsulinemia, elevated IGF-1 (insulin-like growth factor 1), and altered adipokines (leptin/adiponectin ratio)—all of which promote tumor cell proliferation and angiogenesis. Direct vs. Indirect Pathways: GLP-1s lower cancer risk indirectly through substantial adiposity loss and improved insulin sensitivity. However, researchers are also investigating direct GLP-1 receptor signalling in immune cells (e.g., NK cell restoration) and tumor microenvironments. 📊 2. WHAT THE EARLY SIGNALS SHOW: Incidence Reduction: Large retrospective cohort studies show significant risk reductions in colorectal, pancreatic, endometrial, ovarian, and breast cancers compared to traditional anti-diabetic medications like insulin or sulfonylureas. Active Cancer Outcomes: Emerging studies are evaluating whether GLP-1 use during or after active treatment improves recurrence-free survival (RFS) and treatment response (e.g., reversing chemotherapy resistance driven by metabolic dysfunction). 🔬 3. WHAT TO WATCH FOR IN THIS SERIES: Over the next several weeks, I'll be breaking down landmark studies, real-world comparative effectiveness data, and my own upcoming research presentation on GLP-1 use and breast cancer outcomes! 👇 What questions do you have about GLP-1 medications and cancer risks? Leave them below! #GLP1 #Oncology #CancerResearch #Ozempic #Wegovy

About